Cobenfy (xanomeline/trospium chloride; previously KarXT) was accepted for schizophrenia in grownups by the Fda in late September. The medicine has an unique device of activity, which is the very first for schizophrenia in numerous years. Cobenfy targets cholinergic receptors as opposed to harmonizing degrees of dopamine and serotonin, which is what standard irregular antipsychotics
Read More
发布者：David Pierce，转转请注明出处：https://robotalks.cn/promising-schizophrenia-drug-cobenfy-will-face-access-challenges/
